Atara Biotherapeutics, Inc. (ATRA)
NASDAQ: ATRA · Real-Time Price · USD
12.55
+0.33 (2.70%)
At close: Dec 3, 2025, 4:00 PM EST
12.79
+0.24 (1.91%)
After-hours: Dec 3, 2025, 5:06 PM EST
Atara Biotherapeutics Revenue
Atara Biotherapeutics had revenue of $3.45M in the quarter ending September 30, 2025, a decrease of -91.41%. This brings the company's revenue in the last twelve months to $151.93M, up 51.27% year-over-year. In the year 2024, Atara Biotherapeutics had annual revenue of $128.94M with 1,404.02% growth.
Revenue (ttm)
$151.93M
Revenue Growth
+51.27%
P/S Ratio
0.95
Revenue / Employee
$993,007
Employees
153
Market Cap
90.49M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 128.94M | 120.37M | 1,404.02% |
| Dec 31, 2023 | 8.57M | -55.00M | -86.51% |
| Dec 31, 2022 | 63.57M | 43.23M | 212.55% |
| Dec 31, 2021 | 20.34M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ATRA News
- 21 days ago - Atara Biotherapeutics Announces Third Quarter Financial Results and Operational Progress - Business Wire
- 4 weeks ago - Pierre Fabre Pharmaceuticals Announces Transfer from Atara Biotherapeutics of the Biologics License Application (BLA) for Tabelecleucel as Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 2 months ago - 4 Biotechnology Stocks That Outshine In Momentum Amid Strong Technicals - Benzinga
- 3 months ago - Atara Biotherapeutics Announces Changes to Its Board of Directors - Business Wire
- 4 months ago - Atara Biotherapeutics Announces Second Quarter Financial Results and Operational Progress - Business Wire
- 4 months ago - Pierre Fabre Pharmaceuticals Inc. Announces FDA Acceptance and Priority Review of the Biologics License Application (BLA) for Tabelecleucel for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) - PRNewsWire
- 4 months ago - Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease - Business Wire
- 5 months ago - Perre Fabre Pharmaceuticals, Inc. Announces Transfer of Investigational New Drug Application for Tabelecleucel from Atara Biotherapeutics, Inc. - PRNewsWire